<DOC>
	<DOC>NCT00922779</DOC>
	<brief_summary>This single arm study will evaluate the safety and tolerability of ribavirin in combination with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or 1000-1200mg po daily, according to HCV genotype and body weight (&lt; and &gt;75kg)in combination with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is &gt;500 individuals.</brief_summary>
	<brief_title>A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; serological evidence of chronic hepatitis C; detectable serum HCVRNA; liver biopsy findings consistent with a diagnosis of chronic hepatitis C. history or other evidence of a medical condition associated with chronic liver disease other than HCV; coinfection with active hepatitis A or B; hepatocellular carcinoma; patients with severe cardiovascular disease whose condition may worsen due to acute anemia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>